Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1637 1642 1674
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18192108 | DOUBLE-STRANDED RNA THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN AND PHARMACEUTICAL COMPOSITION | Non-Final OA | FUJIFILM Corporation |
| 17797810 | RNA-LOADED NANOPARTICLES AND USE THEREOF FOR THE TREATMENT OF CANCER | Final Rejection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17637427 | TARGETING SLC38A2 IN PANCREATIC CANCER | Non-Final OA | New York University |
| 18365991 | Weight Loss Regimen | Non-Final OA | Board of Regents, The University of Texas System |
| 18309548 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING OR REVERSING OBESITY AND OBESITY-RELATED DISORDERS BY OPSIN 3 REGULATION OF HYPOTHALAMIC MELANOCORTIN RECEPTORS | Non-Final OA | Brown University |
| 15263078 | GENETICALLY ENGINEERED CELLS AS A MODULAR PLATFORM FOR CELL-BASED MEDICINE | Non-Final OA | SRI International |
| 18131892 | SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17416108 | MODULATORS OF HSD17B13 EXPRESSION | Final Rejection | Ionis Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy